BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 26, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Feb. 15, 2005
View Archived Issues
Encysive Stock Moves Up 12 Percent On Thelin Data
Encysive Pharmaceuticals Inc. plans to file a new drug application in April based on pivotal Phase III data showing that Thelin met its primary endpoint in pulmonary arterial hypertension. (BioWorld Today)
Read More
Discovery Laboratories Gets Surfaxin Approvable Letter
Read More
ConjuChem Raises C$21.7M For Upcoming DAC Studies
Read More
Accentia Files For $86M IPO To Fund Trials, Pay Off Debt
Read More
Other News To Note
Read More
U.S. Patent Disclosures
Read More